00:00 , May 17, 2019 |  BC Innovations  |  Product Development

Abeona tackles gene therapy’s problems in cystic fibrosis with chimeric AAVs

As it builds up its preclinical pipeline, Abeona is switching gears to create chimeric AAV vectors that it hopes will do a better job than naturally occurring ones of dialing in the right properties for...
23:24 , May 15, 2019 |  BC Extra  |  Company News

Management tracks: Biogen’s McKenzie departing for CSL; plus Rubius, SanBio, Avita and more

Paul McKenzie is leaving Biogen Inc. (NASDAQ:BIIB) as EVP, pharmaceutical operations & technology to become COO of CSL Ltd. (ASX:CSL). A veteran of Johnson & Johnson (NYSE:JNJ), Bristol-Myers Squibb Co. (NYSE:BMY) and Merck & Co....
14:01 , Mar 25, 2019 |  BC Extra  |  Company News

Thermo Fisher buying gene therapy manufacturer Brammer Bio

Thermo Fisher will pay $1.7 billion to acquire gene and cell therapy contract development and manufacturing company Brammer Bio, giving it vector manufacturing sites in Massachusetts and Florida. Thermo Fisher Scientific Inc. (NYSE:TMO), which chiefly...
21:44 , Feb 12, 2019 |  BC Extra  |  Company News

Management tracks: Sanofi, Alexion, bluebird

Sanofi (Euronext:SAN; NASDAQ:SNY) said Ameet Nathwani will become the pharma's first chief digital officer in addition to his current role of EVP, CMO. Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) said SVP, Business Development and Corporate Strategy Aradhana...
21:18 , Jan 9, 2019 |  BC Extra  |  Company News

Management tracks: Tak joins Flagship, Evercore taps Mehrotra

Paul-Peter Tak has stepped down from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to join Flagship Pioneering as a venture partner. He was GSK's SVP of R&D, chief immunology officer and development lead. Evercore ISI hired Ravi Mehrotra...
01:20 , Nov 28, 2018 |  BC Extra  |  Company News

Management tracks: Abeona, INKEF, Incyte

Abeona Therapeutics Inc. (NASDAQ:ABEO) terminated Carsten Thiel for personal misconduct towards colleagues, less than eight months after hiring him as CEO. The rare genetic disease company named Head of R&D and CMO João Siffert interim...
18:23 , Nov 9, 2018 |  BC Week In Review  |  Company News

Abeona gets rights to RegenxBio gene therapy vector

Gene therapy company RegenxBio Inc. (NASDAQ:RGNX) granted Abeona Therapeutics Inc. (NASDAQ:ABEO) exclusive, worldwide rights to use RegenxBio's NAV adeno-associated virus 9 (AAV9) vector to develop therapies for four lysosomal storage disorders. Abeona will pay RegenxBio...
22:35 , Oct 19, 2018 |  BC Extra  |  Company News

Management tracks: AbbVie, Adverum

AbbVie Inc. (NYSE:ABBV) said EVP and CFO William Chase will retire in mid-2019. Effective immediately, Chase becomes EVP of finance and administration until his retirement and VP and Controller Robert Michael will succeed Chase as...
22:41 , Jul 30, 2018 |  BC Extra  |  Company News

Management Tracks: Abeona, BioDelivery

Gene therapy play Abeona Therapeutics Inc. (NASDAQ:ABEO) hired Max Colao as chief commercial officer. He was SVP of U.S. commercial operations at Alexion Pharmaceuticals Inc. (NASDAQ:ALXN). Allergy company DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) hired Kevin...
15:32 , May 25, 2018 |  BC Week In Review  |  Clinical News

Abeona reports updated data for MPS IIIA gene therapy

Abeona Therapeutics Inc. (NASDAQ:ABEO) said ABO-102 led to significant dose- and time-dependent reductions in CSF and urine heparan sulfate levels through 18 months in a Phase I/II trial to treat mucopolysaccharidosis IIIA (MPS IIIA, Sanfilippo...